{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:10:29Z","timestamp":1778490629254,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early diagnosis and treatment of neovascular age-related macular degeneration (NvAMD) improve vision outcomes. This analysis investigates associations of English indices of multiple deprivation 2019 (IMD2019) with baseline characteristics, key care processes and visual acuity (VA) outcomes for NvAMD in the National Ophthalmology Database (NOD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible eyes started treatment for NvAMD in England between 01\/04\/2020 and 31\/03\/2023. Participating centres with \u226525 eyes with baseline VA and IMD2019 data were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eligible for analysis were 48,583 eyes from 60 English centres. Between decile 1 (most deprived) and decile 10 (least deprived), median age at start of treatment ranged from 79 to 82 years and median baseline VA ranged from 56 to 60 ETDRS letters. After one year of treatment (\u221228 to +84 days), the median number of injections administered ranged from 7 to 8 across deciles. Loss to follow-up was observed in 13.7% eyes in decile 1, and 11.8% in decile 10. Median VA at 12 months ranged from 61 to 65 ETDRS letters across deciles. A \u201cgood\u201d VA outcome (\u226570 ETDRS letters) was achieved by 45.5% in decile 10, compared with 35.9% observed in decile 1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). A \u201cpoor\u201d VA outcome (\u226510 ETDRS letter loss from baseline) occurred in 18.4% of eyes in decile 1 versus 14.5% in decile 10 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients starting NHS-funded treatment in England for NvAMD and living in areas of higher socioeconomic deprivation were typically younger, had lower baseline acuity and achieved worse VA outcomes than those from lower deprivation areas, with little variation in treatment between the deciles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04382-8","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:52:13Z","timestamp":1774353133000},"page":"999-1004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Royal College of Ophthalmologists National Ophthalmology Database age-related macular degeneration (AMD) audit: report 1, associations with socio-economic deprivation in neovascular AMD"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8118-9009","authenticated-orcid":false,"given":"Riddhi","family":"Shenoy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9646-6019","authenticated-orcid":false,"given":"Mable T.","family":"Monachan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8742-9135","authenticated-orcid":false,"given":"Marta","family":"Gruszka-Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-243X","authenticated-orcid":false,"given":"Martin","family":"McKibbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"4382_CR1","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/s41433-024-03050-z","volume":"38","author":"JM Furtado","year":"2024","unstructured":"Furtado JM, Jonas JB, Tapply I, Fernandes AG, Cicinelli MV, Arrigo A, et al. Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a metaanalysis from 2000 to 2020. Eye. 2024;38:2070\u201382.","journal-title":"Eye"},{"key":"4382_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of agerelated macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u2013e16.","journal-title":"Lancet Glob Health"},{"key":"4382_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ajo.2011.09.013","volume":"153","author":"JH Lim","year":"2012","unstructured":"Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012;153:678\u201386.e2.","journal-title":"Am J Ophthalmol"},{"key":"4382_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01468-z","volume":"20","author":"M Weber","year":"2020","unstructured":"Weber M, Dominguez M, Coscas F, Faure C, Baillif S, Kodjikian L, et al. Impact of intravitreal aflibercept dosing regimens in treatment-na\u00efve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW. BMC Ophthalmol. 2020;20:206.","journal-title":"BMC Ophthalmol"},{"key":"4382_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367.","journal-title":"Br J Ophthalmol"},{"key":"4382_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1001\/jamaophthalmol.2016.5314","volume":"135","author":"AC Ho","year":"2017","unstructured":"Ho AC, Albini TA, Brown DM, Boyer DS, Regillo CD, Heier JS. The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good. JAMA Ophthalmol. 2017;135:268\u201373.","journal-title":"JAMA Ophthalmol"},{"key":"4382_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/bjophthalmol-2021-319383","volume":"107","author":"SP Mollan","year":"2023","unstructured":"Mollan SP, Fu DJ, Chuo C-Y, Gannon JG, Lee WH, Hopkins JJ, et al. Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report. Br J Ophthalmol. 2023;107:267\u201374.","journal-title":"Br J Ophthalmol"},{"key":"4382_CR8","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1093\/pubmed\/fdx058","volume":"40","author":"D Shickle","year":"2017","unstructured":"Shickle D, Farragher TM, Davey CJ, Slade SV, Syrett J. Geographical inequalities in uptake of NHS funded eye examinations: Poisson modelling of small-area data for Essex, UK. J Public Health. 2017;40:e171\u2013e9.","journal-title":"J Public Health"},{"key":"4382_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.22599\/bioj.338","volume":"20","author":"L England","year":"2024","unstructured":"England L, O\u2019Connor A. Do socioeconomic inequalities exist within ophthalmology and orthoptics in the UK? A scoping review. Br Ir Orthopt J. 2024;20:31\u201347.","journal-title":"Br Ir Orthopt J"},{"key":"4382_CR10","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1038\/s41433-023-02508-w","volume":"37","author":"TL Wong","year":"2023","unstructured":"Wong TL, Ang JL, Deol S, Buckmaster F, McTrusty AD, Tatham AJ. The relationship between multiple deprivation and severity of glaucoma at diagnosis. Eye. 2023;37:3376\u201381.","journal-title":"Eye"},{"key":"4382_CR11","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41433-023-02774-8","volume":"38","author":"RA Harper","year":"2024","unstructured":"Harper RA, Hooper J, Fenerty CH, Roach J, Bowen M. Deprivation and the location of primary care optometry services in England. Eye. 2024;38:656\u20138.","journal-title":"Eye"},{"key":"4382_CR12","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41433-019-0393-3","volume":"33","author":"P More","year":"2019","unstructured":"More P, Almuhtaseb H, Smith D, Fraser S, Lotery AJ. Socio-economic status and outcomes for patients with age-related macular degeneration. Eye. 2019;33:1224\u201331.","journal-title":"Eye"},{"key":"4382_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.puhe.2014.10.012","volume":"129","author":"JL Yip","year":"2015","unstructured":"Yip JL, Khawaja AP, Chan MP, Broadway DC, Peto T, Luben R, et al. Area deprivation and age related macular degeneration in the EPIC-Norfolk eye study. public health. 2015;129:103\u20139.","journal-title":"public health"},{"key":"4382_CR14","doi-asserted-by":"publisher","first-page":"e001038","DOI":"10.1136\/bmjophth-2022-001038","volume":"7","author":"SD Relton","year":"2022","unstructured":"Relton SD, Chi GC, Andrew L, West RM, Martin M, Santiago C, et al. Associations with visual acuity outcomes after 12 months of treatment in 9401 eyes with neovascular AMD. BMJ Open Ophthalmol. 2022;7:e001038.","journal-title":"BMJ Open Ophthalmol"},{"key":"4382_CR15","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41433-022-02208-x","volume":"37","author":"SD Relton","year":"2023","unstructured":"Relton SD, Chi GC, Lotery AJ, West RM. Real world AMDtoEMRUG, McKibbin M. Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD. Eye. 2023;37:1652\u20138.","journal-title":"Eye"},{"key":"4382_CR16","unstructured":"Ministry of Housing CLG. English indices of deprivation 2019 (IoD2019). Ministry of Housing CLG; 2019."},{"key":"4382_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","volume":"118","author":"PJ Rosenfeld","year":"2011","unstructured":"Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118:523\u201330.","journal-title":"Ophthalmology"},{"key":"4382_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","volume":"120","author":"G-s Ying","year":"2013","unstructured":"Ying G-s, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:122\u20139.","journal-title":"Ophthalmology"},{"key":"4382_CR19","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1136\/bjophthalmol-2014-304959","volume":"98","author":"HE Sharma","year":"2014","unstructured":"Sharma HE, Mathewson PA, Lane M, Shah P, Glover N, Palmer H, et al. The role of social deprivation in severe neovascular age-related macular degeneration. Br J Ophthalmol. 2014;98:1625\u20138.","journal-title":"Br J Ophthalmol"},{"key":"4382_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/bjo.2008.147231","volume":"93","author":"N Acharya","year":"2009","unstructured":"Acharya N, Lois N, Townend J, Zaher S, Gallagher M, Gavin M. Socio-economic deprivation and visual acuity at presentation in exudative age-related macular degeneration. Br J Ophthalmol. 2009;93:627\u20139.","journal-title":"Br J Ophthalmol"},{"key":"4382_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/pubmed\/fdu039","volume":"37","author":"D Shickle","year":"2015","unstructured":"Shickle D, Farragher TM. Geographical inequalities in uptake of NHS-funded eye examinations: small area analysis of Leeds, UK. J Public Health. 2015;37:337\u201345.","journal-title":"J Public Health"},{"key":"4382_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1001\/jamaophthalmol.2024.3132","volume":"142","author":"E Sherman","year":"2024","unstructured":"Sherman E, Niziol LM, Hicks PM, Johnson-Griggs M, Elam AR, Woodward MA, et al. A screening strategy to mitigate vision impairment by engaging adults who underuse eye care services. JAMA Ophthalmol. 2024;142:909\u201316.","journal-title":"JAMA Ophthalmol"},{"key":"4382_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jcjo.2018.01.021","volume":"53","author":"R Aljied","year":"2018","unstructured":"Aljied R, Aubin MJ, Buhrmann R, Sabeti S, Freeman EE. Eye care utilization and its determinants in Canada. Can J Ophthalmol. 2018;53:298\u2013304.","journal-title":"Can J Ophthalmol"},{"key":"4382_CR24","doi-asserted-by":"publisher","first-page":"e000377","DOI":"10.1136\/bmjophth-2019-000377","volume":"5","author":"W Michel","year":"2020","unstructured":"Michel W, Laurent K, Florence C, C\u00e9line F, Isabelle A, Ingrid D, et al. Impact of intravitreal aflibercept dosing regimens in treatment-na\u00c3\u00afve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study. BMJ Open Ophthalmol. 2020;5:e000377.","journal-title":"BMJ Open Ophthalmol"},{"key":"4382_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.oret.2017.09.017","volume":"2","author":"C Framme","year":"2018","unstructured":"Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, et al. Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: twelve-month outcomes of PERSEUS. Ophthalmol Retin. 2018;2:539\u201349.","journal-title":"Ophthalmol Retin"},{"key":"4382_CR26","unstructured":"National Prostate Cancer Audit (NPCA) State of the Nation Report. London: National Cancer Audit Collaborating Centre, Royal College of Surgeons of England, 2025."},{"key":"4382_CR27","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1007\/s00417-024-06573-z","volume":"262","author":"AG Hamedani","year":"2024","unstructured":"Hamedani AG, Chang AY, Chen Y, VanderBeek BL. Disparities in glaucoma and macular degeneration healthcare utilization among persons living with dementia in the United States. Graefes Arch Clin Exp Ophthalmol. 2024;262:3947\u201355.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4382_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ophtha.2023.02.021","volume":"130","author":"RN Khurana","year":"2023","unstructured":"Khurana RN, Li C, Lum F. Loss to follow-up in patients with neovascular age-related macular degeneration treated with anti\u2013VEGF therapy in the United States in the IRIS\u00ae registry. Ophthalmology. 2023;130:672\u201383.","journal-title":"Ophthalmology"},{"key":"4382_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/24741264231173771","volume":"7","author":"AH Nguyen","year":"2023","unstructured":"Nguyen AH, Davoudi S, Dong K, Bains A, Ness S, Subramanian ML, et al. Socioeconomic disparities in patients receiving intravitreal injections for age-related macular degeneration amid the COVID-19 pandemic. J Vitreoretina Dis. 2023;7:376\u201381.","journal-title":"J Vitreoretina Dis"},{"key":"4382_CR30","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","volume":"136","author":"A Obeid","year":"2018","unstructured":"Obeid A, Gao X, Ali FS, Aderman CM, Shahlaee A, Adam MK, et al. Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal antivascular endothelial growth factor injections. JAMA Ophthalmol. 2018;136:1251\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"4382_CR31","doi-asserted-by":"crossref","unstructured":"Kusenda P, Caprnda M, Gabrielova Z, Kukova N, Pavlovic S, Stefanickova J. Understanding loss to follow-up in AMD patients receiving VEGF inhibitor therapy: associated factors and underlying reasons. Diagnostics. 2024;14:400.","DOI":"10.3390\/diagnostics14040400"},{"key":"4382_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4274\/tjo.28003","volume":"47","author":"O Polat","year":"2017","unstructured":"Polat O, \u0130nan S, \u00d6zcan S, Do\u011fan M, K\u00fcsbeci T, Yava\u015f GF, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with agerelated macular degeneration. Turkish J Ophthalmol Turk Oftalmol Derg. 2017;47:205\u201310.","journal-title":"Turkish J Ophthalmol Turk Oftalmol Derg"},{"key":"4382_CR33","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","volume":"38","author":"E Boulanger-Scemama","year":"2015","unstructured":"Boulanger-Scemama E, Querques G, About F, Puche N, Srour M, Mane V, et al. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38:620\u20137.","journal-title":"J Fr Ophtalmol"},{"key":"4382_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/IAE.0000000000003947","volume":"44","author":"EA Meer","year":"2024","unstructured":"Meer EA, Targ S, Zhang N, Hoggatt KJ, Mehta KM, Brodie F. Age-related macular degeneration injection frequency: effects of distance traveled and travel support. Retina. 2024;44:230\u20136.","journal-title":"Retina"},{"key":"4382_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00311-x","volume":"7","author":"S M\u00fcller","year":"2021","unstructured":"M\u00fcller S, Junker S, Wilke T, Lommatzsch A, Schuster AK, Kaymak H, et al. Questionnaire for the assessment of adherence barriers of intravitreal therapy: the ABQ-IVT. Int J Retin Vitreous. 2021;7:43.","journal-title":"Int J Retin Vitreous"},{"key":"4382_CR36","doi-asserted-by":"crossref","unstructured":"Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, Gentile B, Chi GC, Mirt M, et al. Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema 3 treatment management plans: a multi-national qualitative study. Patient Pref Adherence. 2022;16:587\u2013604.","DOI":"10.2147\/PPA.S347713"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04382-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:29:30Z","timestamp":1778488170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04382-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4382"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04382-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7417262\/v1","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MG-G is a member of the Eye editorial board. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}